Trials / Active Not Recruiting
Active Not RecruitingNCT05215574
Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
A Phase 1 Dose Escalation/Dose Finding Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
- Status
- Active Not Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 130 (estimated)
- Sponsor
- NGM Biopharmaceuticals, Inc · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Study of NGM831 as Monotherapy and in Combination with Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
Conditions
- Pancreatic Cancer
- Breast Cancer
- Gastric Cancer
- Non-small Cell Lung Cancer
- Cervical Cancer
- Endocervical Cancer
- Squamous Cell Carcinoma of Head and Neck
- Bladder Urothelial Cancer
- Colorectal Carcinoma
- Esophageal Cancer
- Ovarian Cancer
- Renal Cell Carcinoma
- Prostate Cancer
- Melanoma
- Mesothelioma
- Cholangiocarcinoma
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | NGM831 | Drug: NGM831 NGM831 is given intravenously (IV) every 3 weeks in a 21 day cycle. Multiple dose levels will be evaluated. |
| DRUG | NGM831 plus pembrolizumab (KEYTRUDA®) | Drug: NGM831 NGM831 is given intravenously (IV) every 3 weeks in a 21day cycle. Multiple dose levels will be evaluated. Drug: pembrolizumab (KEYTRUDA®) pembrolizumab (KEYTRUDA®) will be administered intravenously (IV) every 3 weeks in a 21day cycle. |
| DRUG | NGM831 and NGM438 plus pembrolizumab (KEYTRUDA®) | Drug: NGM831 NGM831 is given intravenously (IV) every 3 weeks in a 21-day cycle. Multiple dose levels will be evaluated. Drug: NGM438 NGM438 is given intravenously (IV) every 3 weeks in a 21-day cycle. Multiple dose levels will be evaluated. Drug: pembrolizumab (KEYTRUDA®) pembrolizumab (KEYTRUDA®) will be administered intravenously (IV) every 3 weeks in a 21-day cycle. |
Timeline
- Start date
- 2022-03-31
- Primary completion
- 2025-07-01
- Completion
- 2026-03-01
- First posted
- 2022-01-31
- Last updated
- 2024-10-10
Locations
9 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05215574. Inclusion in this directory is not an endorsement.